In this episode of PxPulse:The Advocacy Chonicles, Atuswege Mwangomale goes deep on the advocacy work behind the passage of Tanzania’s Universal Healthcare Law. Atu serves as Head of Health Programs for Sikika, a Tanzania-based advocacy organization with a long track record of promoting best practices in governmental financing in the health sector, and advocating for improved health outcomes. Sikika, along with AVAC, is also a member of the COMPASS coalition, which uses data and coalitions across Africa to identify strategic campaigns to advance the HIV response. 

Sikika’s advocacy has been crucial to the ultimate passage of Tanzania’s Universal Health Insurance Bill in 2023, but full funding must still be secured for the law to achieve full impact.  

Atu explains the promise of UHC in Tanzania, how Sikika won the trust of government allies, and why working in coalition was essential to success.

In the days and years ahead under a Trump Administration, advocacy for choice, freedom, science, and rights will require deep strategic shifts to protect hard-fought gains in global health generally, and to safeguard policies and programs that advance it. And there will be major implications for the global AIDS response. Joining us to navigate all this and to better understand the landscape for advocacy are Jen Kates from KFF, a nonpartisan health policy research organization, and our own Suraj Madoori.  

  

In this episode of the Advocacy Chronicles, we put the spotlight on the US, on the dismal statistics on access to PrEP in Black communities, on the state of HIV prevention among Black Americans overall, and the work of one advocacy group—PrEP in Black America (PIBA). Danielle Campbell is one of the founders of PIBA and a long-time advocate for HIV prevention and health equity. She joins the Advocacy Chronicles to talk about PIBA’s call to action for an HIV research agenda that prioritizes the needs of Black communities.

The promise of long-acting PrEP has been super-charged this year by studies showing the powerful efficacy of an antiretroviral known as lenacapavir (LEN). 

This episode of PxPulse goes deep on LEN for PrEP. Recorded just days before Gilead’s announcement that PURPOSE 2 also found very high efficacy, Dr. Flavia Kiweewa, a principal investigator of PURPOSE 1, the first trial to announce efficacy, lays out the research findings and what they mean. And Chilufya Kasanda Hampongo of Zambia’s Treatment Advocacy and Literacy Campaign and Mitchell Warren of AVAC talk about how to change a long history of squandered opportunities to get rollout right. 

The PURPOSE1 trials announced findings in June that a twice-yearly injection of LEN was 100% effective among cisgender women, with zero new cases of HIV. And the PURPOSE 2 trial among cisgender men, and trans and non-binary people, was shown to reduce the risk of HIV by 96%. 

LEN now enters a select category, one of five ARV-based options for PrEP that all protect against HIV if you take them.  But many of the people applauding the results from PURPOSE 1 and 2 will tell you that breakthrough science like this is, as hard as it is, is still the easy part. To break the back of the HIV epidemic demands overcoming an altogether different challenge—coordinating and accelerating every step in rolling out new products so that everyone who needs HIV prevention can get it.   

Listen to this podcast to learn what must be done to finally deliver on the promise of highly effective HIV prevention, from pills to rings to injectable PrEP and beyond.  

Resources 

Second Pivotal Trial of Twice-Yearly HIV Prevention Injection Safe and Highly Effective: PURPOSE 2 Trial Among Gay Men, Trans and Nonbinary People, AVAC Press Release 

The Lens on LEN: The basics on injectable lenacapavir as PrEP, AVAC 

Country planning matrix, PrEPWatch 

Moving a Product to the Real World, AVAC 

The long wait for long-acting HIV prevention and treatment formulations, Lancet 

A game-changer for PrEP if access is adequate, Lancet 

Allocation of Non-Commercial CAB for PrEP Supply in Low- and Middle-Income Countries, 2023-2025, AVAC 

Generic Cabotegravir Timelines, AVAC 

UNAIDS Exec Summary, UNAIDS 

Lenacapavir: What it would it take to get the 6-monthly anti-HIV jab to SA, Bhekisisa 

On this episode of PxPulse:The Advocacy Chronicles, Mandisa Tyadi Dukashe, Treatment Technical Lead at the South African National AIDS Council (SANAC) describes her work in helping to inspire and launch a National U=U Campaign in South Africa in 2024.  

On this episode of the Advocacy Chronicles:  A look at advocacy in Uganda for the Dual Prevention Pill (DPP), a new product combining oral PrEP and oral contraception.

Ruth Akulu is a member of the DPP Civil Society Advisory Group, part of the Uganda Country Coordinating Mechanism Board for Global Fund,  and a 2022 AVAC Advocacy Fellow. Akulu talks about her work to mobilize regulatory authorities to prepare for the DPP. And while she was at it, the establishment of a groundbreaking new initiative, the Product Regulator’s Engagement Committee, which is supporting ongoing engagement between government regulators and young women representing their communities. 

To support your advocacy for the DPP and other multipurpose prevention technologies check out AVAC's Advocates' Guide on MPTs  https://avac.org/resource/advocates-guide-to-multipurpose-prevention-technologies-mpts/

]

In this episode,  Nsubuga Allan Mwasa a Ugandan activist, a clinical psychologist,  and a representative of Sexual Minorities Uganda, or SMUG, an organization that has been at the forefront of the fight for LGBTQ rights, talks about how advocates are organizing to survive and challenge Uganda's Anti-Homosexuality Act (AHA), passed one year ago.  A donation to SMUG supports the work of the Strategic Response Team documenting civil rights violations and intensifying persecution of LGBTQI+ Ugandans. Funds have reached a critical low,  click here to donate to SMUG. 

 

SMUG is part of Convening For Equality CFE, a coalition of civil society groups dedicated to challenging Uganda's AHA and other legislation that discriminates against LGBTQI+ individuals. The law has significantly increased discrimination and violence against the LGBTQI+ community, despite widespread international condemnation and ongoing legal challenges.

A new report by the CFE's Strategic Response Team (SRT), UNWANTED, OUTLAWED AND ILLEGAL: THE CRY OF LGBTIQ+ UGANDANS, documents evictions, arrests, imprisonment, forced anal examaminations, and community violence against LGBTQ+ people since the passage of AHA.  

It’s considered one of the most important and most difficult scientific enterprises in the history of modern medicine—the hunt for an HIV vaccine.  It has led to vast knowledge of HIV and the immune system, and to breakthrough technology. But developing an effective HIV vaccine is still out of reach, while HIV incidence remains high in hard-hit places in the world. In this episode, Nina Russell of the Bill & Melinda Gates Foundation talks about where she sees promise in the science, the goals for an HIV vaccine, and why it has an essential role to play alongside the scale-up of PrEP. Go to https://avac.org/resource/an-hiv-vaccine/

Our debut episode of the Advocacy Chronicles features Yvette Raphael, the Executive Director of Advocacy for Prevention of HIV and AIDS (APHA) in South Africa, and a leader in the development of The Choice Manifesto, supported from start to finish by CASPR.

As co-chair of the African Women Prevention Community Accountability Board (AWPCAB), Yvette and other board members launched the manifesto in Kampala, in September 2023, calling for choice in HIV prevention options for women — such as oral and injectable cabotegravir for PrEP, the dapivirine vaginal ring and the Dual Prevention Pill — and a commitment to expanding access to them. A call heard by UNAIDS Executive Director Winnie Byanyima, who was on hand at the launch to endorse the manifesto.  

Yvette, who is also a 2014 AVAC Advocacy Fellow and celebrated as one of South Africa’s leading human rights activists, lays out why The Choice Manifesto matters and how advocates are leveraging it. 

In this episode of PxPulse, we talk about why and how the decisions that shape global health must be made by those facing the greatest risks. As the world evaluates the pandemic response and debates on decolonizing global health gain momentum, equity in global health has never been more urgent. 

This conversation features global health leader and critic, Dr. Madhukar Pai. And two members of the transnational coalition COMPASS Africa, Francis Luwole and Barbra Ncube, offer an up-close look at the coalition’s pioneering new model for power-sharing.

Get more details and resources at https://avac.org/resource/decolonizing-global-health/